Literature DB >> 12097554

Analysis of CD4(+) T-cell responses to human papillomavirus (HPV) type 11 L1 in healthy adults reveals a high degree of responsiveness and cross-reactivity with other HPV types.

O Martin Williams1, Keith W Hart, Eddie C Y Wang, Colin M Gelder.   

Abstract

Human papillomavirus type 11 (HPV-11) infection causes genital warts and recurrent respiratory papillomatosis. While there is compelling evidence that CD4(+) T cells play an important role in immune surveillance of HPV-associated diseases, little is known about human CD4(+) T-cell recognition of HPV-11. We have investigated the CD4(+) T-cell responses of 25 unrelated healthy donors to HPV-11 L1 virus-like particles (VLP). CD4(+) T-cell lines from 21 of 25 donors were established. Cell sorting experiments carried out on cells from six donors demonstrated that the response was located in the CD45RA(low) CD45RO(high) memory T-cell population. To determine the peptide specificity of these responses, epitope selection was analyzed by using 95 15-mer peptides spanning the entire HPV-11 L1 protein. No single region of L1 was immunodominant; responders recognized between 1 and 10 peptides, located throughout the protein, and peptide responses fell into clear HLA class II restricted patterns. Panels of L1 peptides specific for skin and genital HPV were used to show that the L1 CD4(+) T-cell responses were cross-reactive. The degree of cross-reactivity was inversely related to the degree of L1 sequence diversity between these viruses. Finally, responses to HPV-11 L1 peptides were elicited from ex vivo CD45RO(+) peripheral blood mononuclear cells, demonstrating that recognition of HPV-11 was a specific memory response and not due to in vitro selection during tissue culture. This is the first study of CD4(+) T-cell responses to HPV-11 in healthy subjects and demonstrates marked cross-reactivity with other skin and genital HPV types. This cross-reactivity may be of significance for vaccine strategies against HPV-associated clinical diseases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12097554      PMCID: PMC136402          DOI: 10.1128/jvi.76.15.7418-7429.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae.

Authors:  J C Cook; J G Joyce; H A George; L D Schultz; W M Hurni; K U Jansen; R W Hepler; C Ip; R S Lowe; P M Keller; E D Lehman
Journal:  Protein Expr Purif       Date:  1999-12       Impact factor: 1.650

Review 2.  Pathogenesis and treatment of juvenile onset recurrent respiratory papillomatosis.

Authors:  G E Green; N M Bauman; R J Smith
Journal:  Otolaryngol Clin North Am       Date:  2000-02       Impact factor: 3.346

3.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.

Authors:  F Sallusto; D Lenig; R Förster; M Lipp; A Lanzavecchia
Journal:  Nature       Date:  1999-10-14       Impact factor: 49.962

4.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

Authors:  J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz
Journal:  J Pathol       Date:  1999-09       Impact factor: 7.996

5.  High prevalence of human papillomavirus type 16 infection among children.

Authors:  P S Rice; C Mant; J Cason; J M Bible; P Muir; B Kell; J M Best
Journal:  J Med Virol       Date:  2000-05       Impact factor: 2.327

6.  Pediatric respiratory papillomatosis: prognostic role of viral typing and cofactors.

Authors:  F L Rimell; D L Shoemaker; A M Pou; J A Jordan; J C Post; G D Ehrlich
Journal:  Laryngoscope       Date:  1997-07       Impact factor: 3.325

Review 7.  Epidemiology of genital human papillomavirus infection.

Authors:  L Koutsky
Journal:  Am J Med       Date:  1997-05-05       Impact factor: 4.965

8.  Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome.

Authors:  T D de Gruijl; H J Bontkes; J M Walboomers; P Coursaget; M J Stukart; C Dupuy; E Kueter; R H Verheijen; T J Helmerhorst; M F Duggan-Keen; P L Stern; C J Meijer; R J Scheper
Journal:  J Gen Virol       Date:  1999-02       Impact factor: 3.891

9.  Six unrelated HLA-DR-matched adults recognize identical CD4+ T cell epitopes from influenza A haemagglutinin that are not simply peptides with high HLA-DR binding affinities.

Authors:  C Gelder; M Davenport; M Barnardo; T Bourne; J Lamb; B Askonas; A Hill; K Welsh
Journal:  Int Immunol       Date:  1998-02       Impact factor: 4.823

10.  Phenotypic and functional separation of memory and effector human CD8+ T cells.

Authors:  D Hamann; P A Baars; M H Rep; B Hooibrink; S R Kerkhof-Garde; M R Klein; R A van Lier
Journal:  J Exp Med       Date:  1997-11-03       Impact factor: 14.307

View more
  17 in total

Review 1.  Heterologous immunity: immunopathology, autoimmunity and protection during viral infections.

Authors:  Liisa K Selin; Myriam F Wlodarczyk; Anke R Kraft; Siwei Nie; Laurie L Kenney; Roberto Puzone; Franco Celada
Journal:  Autoimmunity       Date:  2011-01-20       Impact factor: 2.815

2.  Human papillomavirus types 16 and 18 DNA load in relation to coexistence of other types, particularly those in the same species.

Authors:  Long Fu Xi; Zoe R Edelstein; Craig Meyers; Jesse Ho; Stephen L Cherne; Mark Schiffman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-08-18       Impact factor: 4.254

3.  Pancreatitis after human papillomavirus vaccination: a matter of molecular mimicry.

Authors:  Mojca Bizjak; Or Bruck; Sonja Praprotnik; Shani Dahan; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

4.  HLA class II polymorphisms and susceptibility to recurrent respiratory papillomatosis.

Authors:  Colin M Gelder; O Martin Williams; Keith W Hart; Siôn Wall; Gareth Williams; Duncan Ingrams; Peter Bull; Mike Bunce; Ken Welsh; Sara E F Marshall; Leszek Borysiewicz
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

5.  Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.

Authors:  Marion Nonn; Manuela Schinz; Klaus Zumbach; Michael Pawlita; Achim Schneider; Matthias Dürst; Andreas M Kaufmann
Journal:  J Cancer Res Clin Oncol       Date:  2003-08-02       Impact factor: 4.553

6.  Late-onset adenosine deaminase deficiency presenting with Heck's disease.

Authors:  Hasibe Artac; Bahar Göktürk; Sefika Elmas Bozdemir; Hatice Toy; Mirjam van der Burg; Ines Santisteban; Michael Hershfield; Ismail Reisli
Journal:  Eur J Pediatr       Date:  2009-12-29       Impact factor: 3.183

7.  RTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection.

Authors:  Sonia Enosse; Carlota Dobaño; Diana Quelhas; John J Aponte; Marc Lievens; Amanda Leach; Jahit Sacarlal; Brian Greenwood; Jessica Milman; Filip Dubovsky; Joe Cohen; Ricardo Thompson; W Ripley Ballou; Pedro L Alonso; David J Conway; Colin J Sutherland
Journal:  PLoS Clin Trials       Date:  2006-05-19

8.  Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination.

Authors:  Benjamin Yang; Andrew Yang; Shiwen Peng; Xiaowu Pang; Richard B S Roden; T-C Wu; Chien-Fu Hung
Journal:  Cell Biosci       Date:  2015-06-25       Impact factor: 7.133

9.  Prevalence of high-risk human papillomavirus types in Mexican women with cervical intraepithelial neoplasia and invasive carcinoma.

Authors:  Rubén López-Revilla; Luz A Martínez-Contreras; Mireya Sánchez-Garza
Journal:  Infect Agent Cancer       Date:  2008-02-28       Impact factor: 2.965

10.  Therapeutic immunisation of rabbits with cottontail rabbit papillomavirus (CRPV) virus-like particles (VLP) induces regression of established papillomas.

Authors:  Vandana A Govan; Edward P Rybicki; Anna-Lise Williamson
Journal:  Virol J       Date:  2008-03-20       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.